NCT05033054View on ClinicalTrials.gov

Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

CompletedOBSERVATIONAL
Enrollment

33

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

January 2, 2025

Study Completion Date

February 1, 2025

Conditions
Kidney Disease, ChronicDiabetes
Interventions
DRUG

SGLT2 inhibitor

Participants will ingest a standard dose of SGLT2i prescribed by the standard of care physician.

Trial Locations (1)

75390

UT Southwestern Medical Center, Dallas

All Listed Sponsors
lead

University of Texas Southwestern Medical Center

OTHER

NCT05033054 - Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4 | Biotech Hunter | Biotech Hunter